IASLC 2017: Combination of Lurbinectedin and Doxorubicin in Relapsed Small Cell Lung Cancer

Key Points

  • Patients treated with lurbinectedin in combination with doxorubicin reached a progression-free survival of 5.3 months, which compares favorably with historical data of topotecan as a single agent.
  • A 37% objective response rate was observed in patients treated with the combination of lurbinectedin and doxorubicin, compared with historical data of objective response rates between 17% and 24% in patients treated with topotecan in relapsed disease.
  • In platinum-sensitive patients, the progression-free survival observed in patients treated with lurbinectedin in combination with doxorubicin increased to up to 6.2 months. Historical data in patients treated with topotecan showed a progression-free survival ranging from 3.25 to 4.3 months.

The final efficacy and safety data obtained from a phase I/II trial combining lurbinectedin (PM1183) with doxorubicin in relapsed small cell lung cancer were presented during a Research Perspectives oral session at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer in Yokohama, Japan (Abstract ID9249). Data from the study were also published in Annals of Oncology.

Major Findings

The study showed that patients treated with lurbinectedin in combination with doxorubicin reached a progression-free survival of 5.3 months, which compares favorably with historical data of topotecan as a single agent (progression-free survival of 3.0–3.5 months). A 37% objective response rate was observed in patients treated with the combination of lurbinectedin and doxorubicin, compared with historical data of objective response rates between 17% and 24% in patients treated with topotecan in relapsed disease.

In platinum-sensitive patients, the progression-free survival observed in patients treated with lurbinectedin in combination with doxorubicin increased to up to 6.2 months. Historical data in patients treated with topotecan showed a progression-free survival ranging from 3.25 to 4.3 months.

The study showed that relevant adverse events—mostly hematologic—were transitory and manageable due to the optimization of the given dose. Lurbinectedin did not produce mucositis, neuropathy, or alopecia.

ATLANTIS Trial

These positive data led to the start of the phase III ATLANTIS trial, which has enrolled 600 patients over 154 centers in 20 countries and seeks to compare the combination of lurbinectedin and doxorubicin vs either topotecan or CAV (cyclophosphamide, doxorubicine, and vincristine) in patients with small cell lung cancer.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement